What about retatrutide and other newer GLP-1 medications Retatrutide, the triple-agonist that targets GLP-1, GIP, and glucagon receptors simultaneously, is not yet commercially available in Mexico through standard pharmacies
In 2024 semaglutide (Wegovy) became the first weight loss drug to also be approved for the reduction of risk of serious cardiovascular events in patients with cardiovascular disease and obesity or overweight
Lipo-Mino Fat Reducing Shots are considered safe for most individuals, but as with any medical procedure, there can be potential side effects
While no natural supplement can fully replace pharmaceutical GLP-1 receptor agonists, certain foods, herbs, and lifestyle habits may help increase the body's own GLP-1 production or improve its effectiveness
Impact of smoking on inflammation: overview of molecular mechanisms